Last edition
News about "Platinum-Resistant Ovarian Cancer (PROC)"
Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer
Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.
Platinum-Resistant Ovarian Cancer (PROC) | 02/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members